Seminar Prof. Krista Rombouts PhD
|When:||Fr 30-11-2018 11:00 - 12:00|
On the occasion of the PhD defence of Adhyatmika
Regenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, Division of Medicine, Royal Free Hospital & University College London, UK
Stellate cells and liver fibrosis: is it time to translate into action?
Hepatic stellate cells (HSCs) are sinusoidal resident vitamin A storing cells and are considered as the most relevant pro-fibrogenic cells operating in acute and chronic liver diseases. During the process of liver injury, these cells undergo phenotypic transformation and become "activated" myofibroblasts-like cells with all features of pro-mitogenic, pro-fibrogenic and pro-inflammatory cells. Multiple etiologies of liver injury can lead to fibrosis, which results from an imbalance between ECM production and degradation. Thus activated HSC orchestrate the responsiveness of the liver to different types of injury, leading to deposition of excessive scar matrix into the interstitium as a wound-healing reaction.
The last decades many investigators have developed new and exciting in vitro and in vivo models to mimic the normal microenvironment of HSC which provide a better opportunity to understand crucial molecular mechanisms that are necessary to develop new clinical therapies. During my talk I will focus on new research data in the field of HSC biology, non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and usage of 2D and novel 3D cell culture systems such 3D ECM human liver scaffolds and 3D bioprinting of cells with human liver ECM ink for improvement of new target identification and drug development.
Contact: Barbro Melgert, Pharmacokinetics, Toxicology & Targeting B.N.Melgert@rug.nl